<DOC>
	<DOCNO>NCT01471444</DOCNO>
	<brief_summary>The goal clinical research study learn combine busulfan clofarabine fludarabine help control disease well previous standard method ( use busulfan fludarabine alone ) patient AML MDS . The safety combination therapy also study .</brief_summary>
	<brief_title>Fludarabine-IV Busulfan ± Clofarabine Allogeneic Hematopoietic Stem Cell Transplantation Acute Myeloid Leukemia ( AML ) Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Busulfan design kill cancer cell bind DNA ( genetic material cell ) , may cause cancer cell die . Busulfan commonly use stem cell transplantation . Clofarabine design interfere growth development cancer cell . Fludarabine design interfere DNA cancer cell , may cause cancer cell die . Study Groups : You randomly assign ( toss coin ) 1 2 study group . - Group 1 receive busulfan , fludarabine , clofarabine . - Group 2 receive busulfan fludarabine . Both group stem cell transplant . The stem cell give vein . The cell travel bone marrow design make healthy , new blood cell several week . For stem cell transplant , day receive stem cell call minus day . The day receive stem cell call Day 0 . The day receive stem cell call plus day . Study Drug Administration Procedures : Both group receive `` test '' dose busulfan vein 45 minute 1 hour . This low-level test dose busulfan check fast busulfan process body clear blood . This information determine amount busulfan receive . You may receive busulfan test dose outpatient week admit hospital inpatient 8 day stem cell transplant . About 11 sample blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test . PK test measure amount study drug body different time point also help determine dose busulfan . These blood sample draw various time receive busulfan next 11 hour . These blood draw repeat first day high-dose busulfan treatment ( Day -6 , 6 day transplant ) . A heparin lock line place vein low number needle stick need draws . If possible PK test perform technical scheduling reason , receive standard fix dose busulfan . On Days -6 -3 , receive fludarabine vein 1 hour , clofarabine ( Group 1 ) vein 1 hour , busulfan vein 3 hour . After transplant , receive tacrolimus , methotrexate , immunosuppressive ( lower immune system ) drug standard manner low risk graft-vs-host disease ( GvHD ) , reaction donor 's immune cell recipient 's body . If go receive transplant HLA-nonidentical unrelated donor , also receive antithymocyte globulin ( ATG ) vein 4 hour 3 day transplant . This drug design weaken immune system reduce risk reject transplant . You receive filgrastim injection skin 1 time day , start 1 week transplant , blood cell level return normal . Filgrastim design help growth white blood cell . While hospital , check side effect part standard care . Blood ( 2 teaspoon ) draw every day check side effect , routine test , check blood count , kidney liver function , check infection . As part standard care , remain hospital 3-4 week transplant . After release hospital , must remain Houston area monitor infection transplant side effect 3 month transplant . During time , return clinic least 1 time week . The following test procedure perform : - You ask feel side effect may . - Blood ( 2 teaspoon ) draw routine test . Around 14-30 day transplant ( transplant `` engrafts '' , `` take '' ) , bone marrow aspirate check status disease . Around Day 30 , 3 , 6 , 12 month transplant , follow test procedure perform : - You physical exam , include measurement vital sign ( blood pressure , heart rate , temperature , breathe rate ) . - You ask feel side effect may . - Blood ( 2 teaspoon ) drawn see well transplant take . - You bone marrow aspiration check status disease . To collect bone marrow aspiration , area hip site numb anesthetic , small amount bone marrow withdrawn large needle . Length Study : You take study 5 year end treatment . You may take study early disease get bad , intolerable side effect , unable follow study direction . You talk study doctor want leave study early . If take study early , still may need return routine post-transplant follow-up visit , transplant doctor decides need . It may life-threatening leave study begin receive study drug receive stem cell . This investigational study . Busulfan fludarabine FDA approve commercially available treatment AML MDS . Clofarabine FDA approve treat type cancer , use AML MDS research . The use study drug together dose level use study investigational . Up 250 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>1 . Patients must one follow hematologic malignancy : ) Acute myeloid leukemia ( AML ) stage cytogenetic riskgroup exception patient AML favorable cytogenetics ( ( 8 ; 21 , inv 16 , ( 15 ; 17 ) achieve complete remission one course induction chemotherapy eligible . Patients treatment relate AML eligible . b ) Myelodysplastic syndrome ( MDS ) intermediate high risk International Prognostic Scoring System score ( IPSS score ) treatment related MDS . Patients low risk MDS eligible fail respond hypomethylating agent therapy azacitidine decitabine . 2 . Age 370 year old . Eligibility pediatric patient determine conjunction MDACC pediatrician . 3 . Performance score &gt; /= 60 Karnofsky PS 0 2 ( ECOG ) ( age &gt; 12 year ) , Lansky PlayPerformance Scale &gt; /= 60 great ( age &lt; 12 year ) . 4 . Negative Beta HCG test woman child bear potential , define postmenopausal 12 month previous surgical sterilization . Women child bear potential must willing use effective contraceptive measure study . 5 . Adequate major organ system function demonstrate : Left ventricular ejection fraction least 40 % . 6 . Pulmonary function test ( PFT ) demonstrate diffusion capacity least 50 % predict . For child &lt; /=7 year age unable perform PFT , oxygen saturation &gt; /=92 % room air pulse oximetry . 7 . Creatinine &lt; 1.5 mg/dL . If question renal function discus study chairman 24 hour creatinine clearance ( clearance &gt; 50 ml/min ) . 8 . Bilirubin &lt; 2.0 x normal ( except Gilbert 's Syndrome ) . SGPT ( ALT ) &lt; 200 . No evidence chronic active hepatitis cirrhosis . 9 . Histocompatible stem cell donor : Patients must HLA match related unrelated donor ( HLA A , B , C DR ) willing donate allogeneic hematopoietic transplantation . High resolution allele level type require donor genotypically identical sibling . 10 . No uncontrolled infection . Protocol PI designé final arbiter uncertainty regard whether previous infection control appropriate ( antibiotic ) therapy . 11 . Patient patient 's legal representative , parent ( ) guardian able sign inform consent . 1 . Positive HIV , HBsAg , HCV viral hepatitis cirrhosis cause . 2 . Prior allogeneic autologous stem cell transplant use myeloablative busulfan total body radiation contain condition regimen define busulfanbased use total dose &gt; /=12 mg/kg give mouth &gt; /=10 mg/kg give IV ; totalbody irradiation ( &gt; 4 Gy ) . 3 . Active prior CNS leukemia , unless complete remission least 3 month . 4 . Previous therapeutic XRT liver part involvedfield radiation . 5 . History serious chronic mental disorder drugabuse accompany document problem compliance therapeutic program . 6 . Lack caregiver early ( 100day ) posttransplant period .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Progression free survival</keyword>
	<keyword>Rate engraftment</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Relapse rate</keyword>
	<keyword>Graft-vs-host disease</keyword>
	<keyword>GvHD</keyword>
	<keyword>Progression-free survival</keyword>
	<keyword>PFS</keyword>
	<keyword>Overall survival</keyword>
	<keyword>OS</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Clofarex</keyword>
	<keyword>Clolar</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>ATG</keyword>
	<keyword>Antithymocyte Globulin</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
</DOC>